Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
Identification of therapeutic targets for steroid-insensitive asthma using models that represent different clinical subtypes of disease Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016
ADAM 33 as a key susceptibility gene for asthma: the contribution of this novel protease to disease pathogenesis Source: Annual Congress 2003 - Proteases at the cutting edge of respiratory disease Year: 2003
Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017
Distribution of therapeutic response in asthma control Source: Eur Respir J 2003; 22: 568 Year: 2003
Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021
In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
A new perspective on concepts of asthma severity, control and optimum treatment Source: Eur Respir J 2009; 33: 704-705 Year: 2009
Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Dose-FEV1 modeling to support future development of AZD2115, a dual acting bronchodilator for the treatment of COPD Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score. Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
TH 2 specific biomarker profile determines steroid responsiveness in severe asthma Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013
Biological and therapeutic implications of the united airways disease concept Source: Annual Congress 2005 - PG18 - Inter-relationships between upper and lower airway diseases Year: 2005
Is the strength of the type-2 (T2) inflammatory biomarker signal important in determining the burden of disease in severe asthma (SA)? Source: Virtual Congress 2020 – Phenotypes of obstructive diseases Year: 2020
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022
Improving asthma therapy through targeting more effective control of inflammation - a European consensus Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Cluster analysis identifies distinct clinical phenotypes with poor treatment responsiveness in asthma. Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018